ArcticZymes Technologies - Board/Management Information 2018

Biotec Pharmacon changes management in the wound care area

(Tromsø 20 September 2018) Stuart Devine, who has been leading Biotec's efforts

in introducing Woulgan® to the market for the last 3 years is leaving Biotec

Pharmacon after a mutual agreement.

Biotec Pharmacon has hired Mr. Finn Ketler to manage the wound care area going

forward. Finn has a long and extensive background within medical devices and

wound care. He spent 14 years in Coloplast with various roles of increasing

responsibility, amongst others managing Coloplast's wound care division. Finn

Ketler listed the Swedish medical device start-up Vigmed at Nasdaq First North

in Stockholm as a CEO. Today Finn is acting as a Selection Committee member in

BioInnovation Institutes (BII) Incubation programme - a position of trust Finn

will continue to have. BII is a Novo Nordisk Foundation initiative.

Finn Ketler is a Danish national and has a M.Sc. from Aarhus Business School.

"I would like to take this opportunity to thank Stuart for his 3 years of hard

work in developing the Woulgan business and also extend a warm welcome to Finn

on the team", says CEO Christian Jørgensen.

The transition of roles will take place over the next quarter.

For more information, please contact:

CEO Christian Jørgensen, tel +47 47 79 24 57

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine

origin used in molecular DNA technologies and diagnostics, representing growth

markets where rapid technological developments are creating a strong demand for

new and improved enzymes.

AI assistant